 |
|
Roles of Gastrointestinal and Adipose Tissue Peptides in Childhood Obesity and Changes After Weight Loss Due to Lifestyle Intervention
Christian L. Roth, MD;
Thomas Reinehr, MD
Arch Pediatr Adolesc Med. 2010;164(2):131-138.
ABSTRACT
Childhood obesity is a global epidemic and associated with an increased risk of hypertension, diabetes mellitus, and coronary heart disease, in addition to psychological disorders. Interventions such as bariatric surgery are highly invasive and lifestyle modifications are often unsuccessful because of disturbed perceptions of satiety. New signaling peptides discovered in recent years that are produced in peripheral tissues such as the gut, adipose tissue, and pancreas communicate with brain centers of energy homeostasis, such as the hypothalamus and hindbrain. This review discusses the major known gut- and adipose tissue–derived hormones involved in the regulation of food intake and energy homeostasis and their serum levels in childhood obesity before and after weight loss as well as their relationship to consequences of obesity. Since most of the changes of gastrointestinal hormones and adipokines normalize in weight loss, pharmacological interventions based on these hormones will likely not solve the obesity epidemic in childhood. However, a better understanding of the pathways of body weight– and food intake–regulating gut- and adipose tissue–derived hormones will help to find new strategies to treat obesity and its consequences.
INTRODUCTION
Research on energy homeostasis regulation in children is increasingly important as obesity is the most important risk factor for the development of the metabolic syndrome and type 2 diabetes mellitus (T2DM) in youth, and the rise in childhood obesity and childhood T2DM are nearly statistically parallel.1 In 2006, the prevalence of obesity in US children reached 17%, and if current trends continue, childhood obesity may reach 20% by 2010.2 Pediatric endocrinology is experiencing a wave of newly identified signaling peptides illuminating the gut-brain axis regulating the body's energy balance, or more thoroughly described as the gut–central and peripheral nervous systems–accessory organ (eg, pancreas, liver) axis. Gut hormones (enterokines) and adipose tissue–derived signaling molecules (adipokines) interact with brain centers in complex, overlapping mechanisms of energy intake and storage. These mechanisms evolved during long periods of hunger in the evolution of man to protect the species from extinction. However, today's modern sedentary lifestyle has turned this evolutionary advantage of storing energy as fat into a high risk of cardiovascular morbidity and mortality. To complicate matters, although body weight is precisely regulated, long-term nutrient excess may change set points of the body energy balance including the gut-brain and the adipose tissue–brain axes. In cases of obesity, this appears to make it even more difficult to reduce overweight, as active species-protecting defense mechanisms maintain an elevated level of body fat.
Understanding the changes that occur in the particular regulators of homeostasis—hormones and peptides—relative to the timing and method of weight reduction in overweight children is fundamental to understanding pediatric obesity. We examined these homeostatic regulators before and after weight reduction in a 1-year lifestyle intervention "Obeldicks."3-4 Briefly, this program is based on physical exercise (1 year), nutrition education and behavior therapy for children and parents separately (first 3 months), and individual psychological care of the child and his or her family (months 4-9). The exercise therapy consists of sports, instruction in physical exercise as part of everyday life, and reduction of the amount of time spent watching television. The nutritional course is based on the prevention concept of the "optimized mixed diet," which is both fat and sugar reduced containing 30% energy intake fat, 15% energy intake proteins, and 55% energy intake carbohydrates including 5% energy intake sugar.4 This lifestyle intervention was effective to reduce overweight over a period of at least 3 years after intervention and improved cardiovascular risk factors such as dyslipidemia, impaired glucose tolerance, and hypertension.3-4 Furthermore, the intima-media thickness5 as a predictor of early cardiovascular changes was reduced in children who participated in this intervention. All these findings proved the clinical relevance of the achieved weight loss.
This article will discuss the major known gut- and adipose tissue–derived peptides involved in the regulation of food intake and energy homeostasis, including changes in some of these signaling molecules observed during weight gain and loss in obese children participating in lifestyle interventions, and describe clues that may be helpful in both short-term and long-term management and treatment of childhood obesity.
MODULATORS OF HUNGER AND SATIETY FROM THE PERIPHERY (GASTROINTESTINAL TRACT AND ADIPOSE TISSUE)
The discovery of the adipose tissue–derived hormone leptin in 1994 elucidated an important negative feedback mechanism of energy balance and how information about energy stores is conveyed to the central nervous system. This and other feedback mechanisms of energy metabolism have been intensively studied in rodent models. They demonstrate that peptides produced in the periphery, such as adipose tissue hormones (leptin, resistin, adiponectin, visfatin, retinol-binding protein 4) and appetite-restraining hormones from the gastrointestinal tract (peptide tyrosine-tyrosine [PYY], glucagon-like peptide 1 [GLP-1], oxyntomodulin, cholecystokinin) and pancreas (insulin, pancreatic polypeptide [PP], amylin), as well as the hunger-mediating hormone ghrelin, are important afferent signals that bind to receptors in the hypothalamus and hindbrain (Figure).6-9
|
|
|
|
Figure. Peripheral regulators and important brain areas of energy homeostasis. Long-term regulators are adipose tissue–derived food intake–inhibiting hormones leptin and adiponectin, whereas hormones produced in the gastrointestinal (GI) tract and pancreas are short-term food intake–inhibiting (peptide tyrosine-tyrosine [PYY], glucagon-like peptide 1 [GLP-1], oxyntomodulin [OXM], cholecystokinin [CCK], pancreatic polypeptide [PP], amylin) or stimulating (ghrelin) signals. Intact lines connect to the hypothalamus (pink); dashed lines, to the hindbrain (blue, solitary tract nucleus).
|
|
|
Gastrointestinal Peptides
Ghrelin is a peptide containing 28 amino acids and was identified in 1999 as a ligand for the secretion of growth hormone secretagogue receptor10 (Table). Ghrelin is produced principally by the stomach and, to a lesser extent, the duodenum32 and is the only known circulating orexigen. Endogenous levels of ghrelin increase before meals and decrease after food intake, suggesting its role in both meal initiation and weight gain.7, 33-34 It has been postulated that both the hyperphagia and potentially the growth hormone deficiency in Prader-Willi syndrome may be related to ghrelin dysregulation, as high circulating levels of ghrelin have been observed in this disorder.35 Less clear is why serum ghrelin levels are decreased in nonsyndromic simple obesity, which may be due to overfeeding and a consequence of metabolic changes associated with obesity, such as insulin resistance.12-13,36-38
|
|
|
|
Table. Effects of Different Gut and Adipose Tissue Hormones on Food Intake and Their Changes in Childhood Obesity and After Weight Loss
|
|
|
Important clues about why some children and not others are successful in maintaining long-term weight loss have been shown in recent studies. Specifically, increased ghrelin levels during weight reduction are considered to be a compensatory mechanism responsible for making weight reduction unsustainable.39 Krohn et al11 showed that the increase of ghrelin levels after weight loss in obese children is correlated with an increase in insulin sensitivity. In a Spanish study of obese children on a calorie-restricted diet, ghrelin levels increased significantly after 3 months of successful weight reduction.13 In the Obeldicks lifestyle intervention, we found no significant changes in ghrelin levels in the children who achieved substantial weight reduction.12 A slow reduction of weight that does not cause an immediate compensatory increase of ghrelin may help stabilize and maintain a lower body weight and prevent a fast regain of weight due to an increase of ghrelin. These are encouraging results because ghrelin is the only known circulating appetite stimulant.7, 33-34
Obestatin is a recently identified peptide derived from the same gene (preproghrelin) as ghrelin and has the opposite effect on weight status, inhibiting food intake and gastrointestinal motility. Obestatin is postulated to antagonize ghrelin's actions on homeostasis and gastrointestinal function.40 Because obestatin and ghrelin are both derived from the same gene,40 one study hypothesized a possible cause of obesity to be an imbalance of circulating obestatin and ghrelin levels.41 Preprandial ghrelin to obestatin ratios were elevated in obese subjects compared with controls, suggesting that a higher ratio may be involved in the etiology and pathophysiology of obesity; however, results from other studies are not conclusive.42-44
A short-term summer camp weight reduction study of 46 obese children demonstrated increased ghrelin and obestatin levels and ghrelin to obestatin ratios after weight reduction.42 In Obeldicks, obestatin levels increased significantly after weight reduction while ghrelin levels did not change significantly, a pattern that may be important to stabilize the lower body weight and prevent recurrence of weight gain.38
Peptide YY is a 36–amino acid peptide originally isolated and characterized in 198045 (Table). There are 2 endogenous forms, PYY1-36 and PYY3-36, abundant in humans. Peptide YY is a gut-derived hormone released postprandially by the L cells of the lower intestine that inhibits gastric acid secretion and motility through neural pathways.46-50 Peptide YY belongs to the family of peptides that includes neuropeptide Y and PP, which mediate their effects via G protein–coupled neuropeptide Y2, Y4, Y5, and Y6 receptors and display different tissue distributions and functions.51 PYY1-36 binds to all known Y receptor subtypes, whereas PYY3-36 shows affinity for the Y1 and Y5 receptor subtypes and high affinity for the inhibitory Y2 receptor subtype. PYY3-36 binding to the Y2 receptor subtype inhibits the orexigenic neuropeptide Y in the hypothalamus, causing short-term inhibition of food intake, especially high-fat meals.8, 52-54 Studies in rodents identified the hypothalamus, vagus, and brainstem regions as sites of action.55 Functional magnetic resonance imaging of normal-weight humans infused with PYY3-36 to circulating concentrations similar to those observed postprandially showed modulated neuronal activity within the hypothalamus, brainstem, and midbrain regions involved in food reward processing.56 This suggests that PYY3-36 affects feeding by action on homeostatic and hedonic brain circuits. Peptide YY may also affect energy expenditure.57 Among other studies confirming this effect,58-59 peripheral infusion of PYY3-36 in humans showed increased energy expenditure and fat oxidation rates.60
In obese children, levels of the anorexigenic hormone PYY are low. After efficient weight loss in Obeldicks, PYY levels significantly increased, reaching levels comparable with normal-weight individuals.14 Once effective weight loss has been achieved, the anorectic effect of PYY may help stabilize weight and thereby prevent later weight gain in patients whose PYY levels increased to normal levels.
Glucagon-like peptide 1 is a gut hormone synthesized from enteroendocrine L cells of the small and large intestine and secreted in 2 major molecular forms, GLP-17-36 amide and GLP-17-37, with equipotent biological activity (Table). Glucagon-like peptide 1 binds receptors in key appetite-related sites in the hypothalamus (eg, arcuate and dorsomedial nuclei) and the brainstem (specifically the nucleus of the solitary tract).15, 61-62 It is the most potent insulin-stimulating hormone known to date, it suppresses glucagon secretion, and it inhibits gastric emptying and acid secretion. In obese children, an attenuated GLP-1 response may contribute to impaired insulin response, leading to T2DM.61-63 Glucagon-like peptide 1 may also reduce energy intake and enhance satiety, likely through the aforementioned delay of gastric emptying and specific GLP-1 receptors in the central nervous system. Its role in childhood obesity is poorly understood, with contradictory post–weight loss level changes reported in the literature.15-18,61-68
Obese children participating in Obeldicks showed significant decreases in GLP-1 levels. At baseline, GLP-1 levels did not differ significantly between obese and lean children. The glucose levels remained static and the decreases in GLP-1 levels were significantly correlated with decreases in insulin levels and insulin resistance index scores.16
Oxyntomodulin is a 37–amino acid peptide that, like GLP-1, is a product of the preproglucagon gene (Table). It is released into the circulation system postprandially and when administered either centrally or peripherally in rodent models or peripherally in humans reduces food intake.19 Oxyntomodulin is equally effective as GLP-1 at inhibiting food intake even though it is thought to do so through a different pathway.
Cholecystokinin was the first gut hormone implicated in the control of appetite by reducing food intake.21 Cholecystokinin is a meal termination signal released postprandially from the gastrointestinal tract (mostly upper small intestine), reducing both meal size and meal duration. After eating, cholecystokinin levels remain elevated up to 5 hours and stimulate gall bladder contraction, pancreatic enzyme release, and intestinal motility, which in turn affect gastric emptying. The alimentary cholecystokinin receptor, CCKA, is present on the vagus nerve, enteric neurons, brainstem, and dorsomedial nucleus of the hypothalamus. Cholecystokinin likely mediates its effect on appetite regulation by crossing the blood-brain barrier where it acts on receptors in the dorsomedial nucleus of the hypothalamus to reduce levels of neuropeptide Y, a potent appetite-stimulating peptide. However, studies in children are missing so far.
Pancreatic Hormones and Peptides
Insulin plays an extremely important role in energy homeostasis (Table). Insulin receptors are expressed in different hypothalamic nuclei. After passing the blood-brain barrier, insulin exerts appetite-inhibiting effects. In rodents, it was proven that insulin administered intracerebroventricularly inhibits food intake by activation of the insulin receptor substrate–phosphatidylinositol 3-kinase (IRS-PI3K) pathway in ventromedial neurons of the hypothalamus.69-70 Numerous insulin knockout models show that decreased central insulin effect leads to the obese phenotype. Most recent research results show that central insulin resistance can be caused by hypothalamic inflammation due to nutrient excess,71 causing reduced IRS-PI3K signaling, which thereby contributes to increased appetite and the maintenance of elevated body weight.72 In childhood obesity, increased blood insulin levels indicate peripheral and central insulin resistance. Successful reduction of overweight leads to reduction of hyperinsulinemia and improved insulin sensitivity.22-23
Pancreatic polypeptide is a 36–amino acid peptide produced under vagal control by peripheral cells of the endocrine pancreatic islets, and to a lesser extent in the exocrine pancreas, colon, and rectum, in response to a meal and insulin-induced hypoglycemia (Table).47, 73 Administration of pharmacological doses of PP in humans decreases food intake for 24 hours74 and inhibits the gastric emptying rate, exocrine pancreatic secretion, and gallbladder motility.75
Changes in PP levels and their relation to the anorexigenic hormones insulin and leptin were studied in Obeldicks.25 At baseline, obese subjects had lower PP concentrations compared with lean controls.25 Following lifestyle intervention, PP concentrations significantly increased and tended to normalize in the children who achieved substantial weight loss in comparison with children who did not lose weight.25 Yet, the changes in PP concentrations did not significantly correlate to changes of insulin and leptin concentrations.25
Amylin is a 37–amino acid polypeptide synthesized and released together with insulin by the pancreatic beta cells in response to nutritional input and contributes to glycemic and appetite control (Table).26, 76 Amylin is a satiety peptide, causing a reduction of the meal size and inhibition of gastric emptying. In addition, amyloid depositions that have been detected in pancreatic islets of T2DM play a central role in the development of beta-cell failure in T2DM.27
In obese children, amylin levels were significantly higher as compared with lean controls.26 Substantial weight loss in Obeldicks led to a significant decrease of amylin concentrations.26 Moreover, the increase of amylin levels in childhood was related to hypersecretion of insulin.26
Hormones Secreted by Adipose Tissue and Cytokines
Adipose tissue is not only important in energy storage, but it is also very active in producing hormones and cytokines (adipokines), which play a role in the pathogenesis of obesity-associated illnesses. Proinflammatory adipokines produced in adipose tissue are leptin, resistin, plasminogen activator inhibitor-1, interleukin 6, and tumor necrosis factor  . Several studies demonstrated higher levels of inflammatory markers in obese children than in normal-weight children77-81 and some of these could be normalized by lifestyle intervention.77 Adipokines are a possible link between insulin resistance and adiposity. The production of interleukin 6 leads to the increase of C-reactive protein, which represents a cardiovascular risk factor.82
Leptin is a 167–amino acid peptide formed in adipose tissue, forwarding information regarding energy supply and peripheral energy storage in adipose tissue to the brain, specifically the hypothalamus (Table). Leptin production is stimulated by insulin and glucocorticoids. The leptin receptor is a single-transmembrane domain receptor of the cytokine receptor family, which activates Januskinase2 in the signal transduction pathway and like insulin, activates IRS-PI3K in neurons of the ventromedial hypothalamus, whereby it induces central appetite inhibition and stimulates energy expenditure by increasing the central sympathetic tone. A high density of leptin receptors was found in the hypothalamic arcuate nucleus and the ventromedial hypothalamus nucleus.20, 83 Leptin has a soluble receptor that represents the main binding site for leptin in blood and may be a negative regulator of free leptin.84
Leptin's homeostatic effect is anorexigenic, invoking satiety and ceasing nutritional intake. Leptin levels circulating in the blood correlate with the amount of adiposal tissue mass. Although it would seem that increased levels of leptin in overweight individuals would lead to appetite suppression and lower food intake, this does not occur because increased fat mass also leads to leptin resistance and decreased leptin signaling in the brain.72 This resistance then may lead to ineffective appetite inhibition and changes the set point of energy homeostasis, resulting in a defense of a higher level of body fat. Leptin deficiency in obese individuals is very rare and is caused by a homozygous ob gene mutation. Only a few patients and families have been reported in the literature. In these individuals, leptin levels are low and leptin therapy has been proven to be a causal treatment of obesity.24 In most obese individuals, however, serum leptin levels are upregulated because of the increased fat mass and leptin resistance, and leptin levels fall after successful weight loss,28-29 while decreased serum soluble receptor concentrations in obese children increase after weight loss.29
Adiponectin is synthesized and secreted exclusively by adipose tissue (Table). It exerts anti-inflammatory effects and appetite-restraining effects and counters insulin resistance, thereby offering protective mechanisms against the development of both T2DM and cardiovascular disease.82 Adiponectin also affects thermogenesis and adiponectin receptors are expressed in various peripheral tissues, including muscle, liver, and hypothalamus.85-86 The central appetite-adjusting mechanisms of adiponectin are not yet fully understood. Interestingly, adiponectin levels are reduced in states of obesity and T2DM.30-31 Adiponectin has anti-inflammatory properties and negatively correlates with cytokine levels and insulin resistance. Low adiponectin levels might play a role in the development of the metabolic syndrome and cardiovascular disease.30-31
In Obeldicks, adiponectin levels significantly increased and insulin resistance significantly improved in a parallel manner in the children who lost weight.30 In an even more recent study, Jeffery et al31 also studied this negative correlation of adiponectin levels in obese children and its role in mediating cardiovascular disease in children. They found clear links between adiponectin and features of the metabolic syndrome.
Resistin is another hormone secreted by adipose tissue and is involved in insulin sensitivity. It has been shown to modulate both glucose tolerance and lipid metabolism in vivo and in vitro.87 Although some data are contradictory, it seems that insulin might inhibit resistin secretion; however, recent animal models show that insulin is not the major regulator of resistin.88
Two longitudinal adult analyses reported serum resistin changes to be positively correlated with changes in fat mass or weight loss,89-90 yet other adult studies reported no correlations.91-93 Resistin serum levels were studied in obese children after 1 year of weight loss.94 Girls demonstrated higher resistin concentrations than boys, but there were no differences of resistin levels between lean and obese children, and there were no significant changes after weight loss.94
Retinol-binding protein 4 (RBP4) is a recently identified adipokine secreted primarily from adipose tissue with some secretion by the liver. It is a proposed link between obesity and insulin resistance.95 In normal mice, elevated RBP4 levels caused insulin resistance in muscle and increased hepatic gluconeogenesis, whereas RBP4 gene knockout mice had increased insulin sensitivity.95
In adults96-97 and children79, 98-99 with obesity and T2DM, elevated RBP4 levels have been correlated with insulin resistance. Two recent studies showed that lifestyle intervention almost reversed elevated RBP4 levels in obese children.79, 99 In our lifestyle intervention,99 children with substantial weight loss demonstrated a significant decrease of RBP4 levels in a parallel manner to blood pressure and triglycerides and insulin levels. These data suggest a link between RBP4, obesity, and markers of the metabolic syndrome.
Visfatin/NAMPT is a recently identified adipocytokine from visceral fat that was found in higher concentrations in obese than in nonobese children.100 Visfatin, originally named pre–B cell colony-enhancing factor, is from the same gene that encodes nicotinamide 5-phosphoribosyl-1-pyrophosphate transferase (NAMPT), an enzyme important in mammalian nicotinamide adenine dinucleotide (NAD+) biosynthesis.101 The relationship between visfatin/NAMPT and the parameters of glucose metabolism and insulin resistance is uncertain because of contradicting data102-107 potentially attributed to differences in immunoassay specificity.108 Recent evidence indicates haplodeficiency and chemical inhibition of NAMPT may cause defects in NAD+ biosynthesis.101 Alterations in NAD levels could alter activities of important enzymes in metabolic pathways such as glycolysis or fatty acid oxidation in pancreatic beta cells.101, 109
SOME EXAMPLES OF PHARMACOLOGICAL APPROACHES
After the appetite-inhibiting effect of leptin had been discovered, it was hoped that administration of leptin might be a cure for obesity. The attempts were disappointing, mostly because simple obesity results in leptin resistance. Only in very rare patients with congenital leptin deficiency does leptin treatment lead to a strong long-term reduction of overweight.24 Some of the gut hormones, such as GLP-1 and CCK, have a very short half-life of a few minutes in the circulation because of rapid degradation, thus limiting their use as antiobesity drugs. However, exendin-4 is a long-acting GLP-1 receptor agonist that has recently been approved by the US Food and Drug Administration for the treatment of T2DM and has also been associated with weight loss.110 Preliminary data from rat models suggest that oxyntomodulin may be useful in treating obesity.111 One such rodent study suggested that oxyntomodulin exerts its anorectic effect through the GLP-1 receptor, as it was ineffective in GLP-1 receptor knockout mice.112 In a recent 4-day human study, oxyntomodulin not only promoted weight loss but increased energy expenditure by more than 25%.113
GLP-1 and the amylin analogue pramlintide appear to decrease weight in patients with T2DM, which is an important secondary goal in treating these patients.114 Pharmaceutical studies have recently been performed to explore amylin's therapeutic potential for treating both obesity and diabetes.114-116 Traditional pharmacotherapies to treat T2DM often exacerbate obesity, undermining any benefits of improved glycemic control as well as patients' compliance with the treatment. The addition of leptin after amylin pretreatment elicited even greater weight loss compared with both monotherapy conditions, providing both nonclinical and clinical evidence that integrated neurohormonal approaches to obesity pharmacotherapy may facilitate more successful weight loss by emulating naturally occurring synergies.116 Administration of PYY in obese humans has been reported to reduce food intake in the short-term.117 Several gut hormone–based treatments for obesity are under investigation in phase 2 and 3 clinical trials, and many more are in the pipeline.115 These gut peptides need to be injected. Orally active inhibitors of the incretin-degrading enzyme dipeptidyl peptidase-IV offer an alternative.118
CONCLUSIONS
Probably the most important conclusion to be made from the data presented herein is that the pathologies affecting energy homeostasis in obese children have at least as much to do with the endocrine phenomena that are involved in the communication between peripheral tissues (gut, adipose tissue) and the brain as they have to do with genetics and sociocultural and lifestyle factors. This implies that the solutions to this serious, ever-escalating threat to both the life span and life quality of our children are also embedded in a better understanding of the endocrine status of the obese child. The majority of the changes of gut hormones and adipokines observed in obese children are reversible after weight loss, and therefore, pharmacological interventions based on these hormones will likely not solve the obesity epidemic in childhood. However, successful solutions have much to do with the length and thoroughness of interventions; there are no simple, quick-fix pharmaceutical solutions to sustainable weight loss. Understanding the pathways of body weight– and food intake–regulating gut- and adipose tissue–derived hormones will help to find better answers that can effectively combat both childhood obesity as well as the plethora of pathologies that it either causes or exacerbates.
AUTHOR INFORMATION
Correspondence: Christian L. Roth, MD, Division of Endocrinology, Seattle Children's Hospital Research Institute, 1900 Ninth Ave, Seattle, WA 98101 (christian.roth{at}seattlechildrens.org).
Accepted for Publication: October 6, 2009.
Author Contributions: Study concept and design: Roth. Analysis and interpretation of data: Roth and Reinehr. Drafting of the manuscript: Roth. Critical revision of the manuscript for important intellectual content: Roth and Reinehr. Statistical analysis: Roth. Obtained funding: Reinehr. Administrative, technical, and material support: Roth. Study supervision: Roth and Reinehr.
Financial Disclosure: None reported.
Author Affiliations: Seattle Children's Research Institute, Seattle, Washington (Dr Roth); and Vestische Hospital for Children and Adolescents Datteln, Institute for Pediatric Nutrition Medicine, University of Witten/Herdecke, Datteln, Germany (Dr Reinehr).
REFERENCES
1. Fagot-Campagna A, Pettitt DJ, Engelgau MM; et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr. 2000;136(5):664-672.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
2. Koplan JP, ed. Progress in Preventing Childhood Obesity: How Do We Measure Up? Washington, DC: National Academies Press; 2006.3. Reinehr T, Temmesfeld M, Kersting M, de Sousa G, Toschke AM. Four-year follow-up of children and adolescents participating in an obesity intervention program. Int J Obes (Lond). 2007;31(7):1074-1077.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
4. Reinehr T, de Sousa G, Toschke AM, Andler W. Long-term follow-up of cardiovascular disease risk factors in children after an obesity intervention. Am J Clin Nutr. 2006;84(3):490-496.
FREE FULL TEXT
5. Wunsch R, de Sousa G, Toschke AM, Reinehr T. Intima-media thickness in obese children before and after weight loss. Pediatrics. 2006;118(6):2334-2340.
FREE FULL TEXT
6. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425-432.
FULL TEXT
| PUBMED
7. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407(6806):908-913.
FULL TEXT
| PUBMED
8. Batterham RL, Cowley MA, Small CJ; et al. Gut hormone PYY-(3-36) physiologically inhibits food intake. Nature. 2002;418(6898):650-654.
FULL TEXT
| PUBMED
9. Schwartz MW, Seeley RJ, Campfield LA, Burn P, Baskin DG. Identification of targets of leptin action in rat hypothalamus. J Clin Invest. 1996;98(5):1101-1106.
WEB OF SCIENCE
| PUBMED
10. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from the stomach. Nature. 1999;402(6762):656-660.
FULL TEXT
| PUBMED
11. Krohn K, Boczan C, Otto B; et al. Regulation of ghrelin is related to estimated insulin sensitivity in obese children. Int J Obes (Lond). 2006;30(10):1482-1487.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
12. Reinehr T, Roth CL, Alexy U, Kersting M, Kiess W, Andler W. Ghrelin levels before and after reduction of overweight due to a low-fat high-carbohydrate diet in obese children and adolescents. Int J Obes (Lond). 2005;29(4):362-368.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
13. Soriano-Guillén L, Barrios V, Campos-Barros A, Argente J. Ghrelin levels in obesity and anorexia nervosa: effect of weight reduction or recuperation. J Pediatr. 2004;144(1):36-42.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
14. Roth CL, Enriori PJ, Harz K, Woelfle J, Cowley M, Reinehr T. Peptide YY is a regulator of energy homeostasis in obese children before and after weight loss. J Clin Endocrinol Metab. 2005;90(12):6386-6391.
FREE FULL TEXT
15. Bloom S, Wynne K, Chaudhri O. Gut feeling—the secret of satiety? Clin Med. 2005;5(2):147-152.
WEB OF SCIENCE
| PUBMED
16. Reinehr T, de Sousa G, Roth CL. Fasting glucagon-like peptide-1 and its relation to insulin in obese children before and after weight loss. J Pediatr Gastroenterol Nutr. 2007;44(5):608-612.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
17. Verdich C, Toubro S, Buemann B, Lysgård Madsen J, Juul Holst J, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety: effect of obesity and weight reduction. Int J Obes Relat Metab Disord. 2001;25(8):1206-1214.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
18. Adam TC, Jocken J, Westerterp-Plantenga MS. Decreased glucagon-like peptide 1 release after weight loss in overweight/obese subjects. Obes Res. 2005;13(4):710-716.
WEB OF SCIENCE
| PUBMED
19. Cohen MA, Ellis SM, le Roux CW; et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab. 2003;88(10):4696-4701.
FREE FULL TEXT
20. Murphy KG, Dhillo WS, Bloom SR. Gut peptides in the regulation of food intake and energy homeostasis. Endocr Rev. 2006;27(7):719-727.
FREE FULL TEXT
21. Smith GP, Gibbs J. Cholecystokinin: a putative satiety signal. Pharmacol Biochem Behav. 1975;3(1)(suppl):135-138.
WEB OF SCIENCE
| PUBMED
22. Savoye M, Shaw M, Dziura J; et al. Effects of a weight management program on body composition and metabolic parameters in overweight children: a randomized controlled trial. JAMA. 2007;297(24):2697-2704.
FREE FULL TEXT
23. Reinehr T, Kiess W, Kapellen T, Andler W. Insulin sensitivity among obese children and adolescents, according to degree of weight loss. Pediatrics. 2004;114(6):1569-1573.
FREE FULL TEXT
24. Lustig RH, Sen S, Soberman JE, Velasquez-Mieyer PA. Obesity, leptin resistance, and the effects of insulin reduction. Int J Obes Relat Metab Disord. 2004;28(10):1344-1348.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
25. Reinehr T, Enriori PJ, Harz K, Cowley MA, Roth CL. Pancreatic polypeptide in obese children before and after weight loss. Int J Obes (Lond). 2006;30(10):1476-1481.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
26. Reinehr T, de Sousa G, Niklowitz P, Roth CL. Amylin and its relation to insulin and lipids in obese children before and after weight loss. Obesity (Silver Spring). 2007;15(8):2006-2011.
FULL TEXT
| PUBMED
27. Kahn SE, Andrikopoulos S, Verchere CB. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes. 1999;48(2):241-253.
ABSTRACT
28. Laimer M, Ebenbichler CF, Kaser S; et al. Weight loss increases soluble leptin receptor levels and the soluble receptor bound fraction of leptin. Obes Res. 2002;10(7):597-601.
WEB OF SCIENCE
| PUBMED
29. Reinehr T, Kratzsch J, Kiess W, Andler W. Circulating soluble leptin receptor, leptin, and insulin resistance before and after weight loss in obese children. Int J Obes (Lond). 2005;29(10):1230-1235.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
30. Reinehr T, Roth C, Menke T, Andler W. Adiponectin before and after weight loss in obese children. J Clin Endocrinol Metab. 2004;89(8):3790-3794.
FREE FULL TEXT
31. Jeffery AN, Murphy MJ, Metcalf BS; et al. Adiponectin in childhood. Int J Pediatr Obes. 2008;3(3):130-140.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
32. Ariyasu H, Takaya K, Tagami T; et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab. 2001;86(10):4753-4758.
FREE FULL TEXT
33. Nakazato M, Murakami N, Date Y; et al. A role for ghrelin in the central regulation of feeding. Nature. 2001;409(6817):194-198.
FULL TEXT
| PUBMED
34. Wren AM, Small CJ, Ward HL; et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology. 2000;141(11):4325-4328.
FREE FULL TEXT
35. Cummings DE, Clement K, Purnell JQ; et al. Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med. 2002;8(7):643-644.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
36. Williams DL, Grill HJ, Cummings DE, Kaplan JM. Overfeeding-induced weight gain suppresses plasma ghrelin levels in rats. J Endocrinol Invest. 2006;29(10):863-868.
WEB OF SCIENCE
| PUBMED
37. Cummings DE. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav. 2006;89(1):71-84.
FULL TEXT
| PUBMED
38. Reinehr T, de Sousa G, Roth CL. Obestatin and ghrelin levels in obese children and adolescents before and after reduction of overweight. Clin Endocrinol (Oxf). 2008;68(2):304-310.
PUBMED
39. De Ambrogi M, Volpe S, Tamanini C. Ghrelin: central and peripheral effects of a novel peptydil hormone. Med Sci Monit. 2003;9(9):RA217-RA224.
PUBMED
40. Zhang JV, Ren PG, Avsian-Kretchmer O; et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science. 2005;310(5750):996-999.
FREE FULL TEXT
41. Guo ZF, Zheng X, Qin YW, Hu JQ, Chen SP, Zhang Z. Circulating preprandial ghrelin to obestatin ratio is increased in human obesity. J Clin Endocrinol Metab. 2007;92(5):1875-1880.
FREE FULL TEXT
42. Zou CC, Liang L, Wang CL, Fu JF, Zhao ZY. The change in ghrelin and obestatin levels in obese children after weight reduction. Acta Paediatr. 2009;98(1):159-165.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
43. Zizzari P, Longchamps R, Epelbaum J, Bluet-Pajot MT. Obestatin partially affects ghrelin stimulation of food intake and growth hormone secretion in rodents. Endocrinology. 2007;148(4):1648-1653.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
44. Haider DG, Schindler K, Prager G; et al. Serum retinol-binding protein-4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab. 2007;92(3):1168-1171.
FREE FULL TEXT
45. Tatemoto K, Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature. 1980;285(5764):417-418.
FULL TEXT
| PUBMED
46. Pappas TN, Debas HT, Goto Y, Taylor IL. Peptide YY inhibits meal-stimulated pancreatic and gastric secretion. Am J Physiol. 1985;248(1, pt 1):G118-G123.
WEB OF SCIENCE
| PUBMED
47. Wynne K, Stanley S, McGowan B, Bloom S. Appetite control. J Endocrinol. 2005;184(2):291-318.
FREE FULL TEXT
48. Wettergren A, Petersen H, Orskov C, Christiansen J, Sheikh SP, Holst JJ. Glucagon-like peptide.17-36 amide and peptide YY form the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol. 1994;29(6):501-505.
WEB OF SCIENCE
| PUBMED
49. Chen CH, Rogers RC. Central inhibitory action of peptide YY on gastric motility in rats. Am J Physiol. 1995;269(4, pt 2):R787-R792.
WEB OF SCIENCE
| PUBMED
50. Oh NG, Son GM, Sin JY, Ding XZ, Adrian TE. Time-course of morphologic changes and peptide YY adaptation in ileal mucosa after loop ileostomy in humans. Dis Colon Rectum. 2005;48(6):1287-1294.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
51. Cabrele C, Beck-Sickinger AG. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family. J Pept Sci. 2000;6(3):97-122.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
52. Lin S, Boey D, Herzog J. NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides. 2004;38(4):189-200.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
53. Keire DA, Mannon P, Kobayashi M, Walsh JH, Solomon TE, Reeve JR Jr. Primary structures of PYY, [Pro34]PYY, and PYY-(3-36) confer different conformations and receptor selectivity. Am J Physiol Gastrointest Liver Physiol. 2000;279(1):G126-G131.
FREE FULL TEXT
54. Stanley S, Wynne K, Bloom S. Gastrointestinal satiety signals, III: glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide. Am J Physiol Gastrointest Liver Physiol. 2004;286(5):G693-G697.
FREE FULL TEXT
55. Karra E, Chandarana K, Batterham RL. The role of peptide YY in appetite regulation and obesity. J Physiol. 2009;587(pt 1):19-25.
FREE FULL TEXT
56. Batterham RL, Ffytche DH, Rosenthal JM; et al. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature. 2007;450(7166):106-109.
FULL TEXT
| PUBMED
57. Guo Y, Ma L, Enriori PJ; et al. Physiological evidence for the involvement of peptide YY in the regulation of energy homeostasis in humans. Obesity (Silver Spring). 2006;14(9):1562-1570.
FULL TEXT
| PUBMED
58. Doucet E, Laviolette M, Imbeault P, Strychar I, Rabasa-Lhoret R, Prud'homme D. Total peptide YY is a correlate of postprandial energy expenditure but not of appetite or energy intake in healthy women. Metabolism. 2008;57(10):1458-1464.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
59. Boey D, Lin S, Enriquez RF; et al. PYY transgenic mice are protected against diet-induced and genetic obesity. Neuropeptides. 2008;42(1):19-30.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
60. Sloth B, Holst JJ, Flint A, Gregersen NT, Astrup A. Effects of PYY1–36 and PYY3–36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab. 2007;292(4):E1062-E1068.
FREE FULL TEXT
61. Bojanowska E. Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress. Med Sci Monit. 2005;11(8):RA271-RA278.
WEB OF SCIENCE
| PUBMED
62. Gutzwiller JP, Degen L, Heuss L, Beglinger C. Glucagon-like peptide 1 (GLP-1) and eating. Physiol Behav. 2004;82(1):17-19.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
63. Cancelas J, Sancho V, Villanueva-Penacarrillo ML; et al. Glucagon-like peptide-1 content of intestinal tract in adult rats injected with streptozotocin either during neonatal period or 7 d before sacrifice. Endocrine. 2002;19(3):279-286.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
64. Rask E, Olsson T, Soderberg S; et al, Northern Sweden Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA). Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care. 2001;24(9):1640-1645.
FREE FULL TEXT
65. Scrocchi LA, Brown TJ, MaClusky N; et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med. 1996;2(11):1254-1258.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
66. Ehlers MR, Klaff LJ, D’Alessio DA; et al. Recombinant glucagon-like peptide-1 (7-36) amide lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes. Horm Metab Res. 2003;35(10):611-616.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
67. Meier JJ, Gallwitz B, Schmidt WE, Nauck MA. Glucagon-like peptide 1 as a regulator of food intake and body weight; therapeutic perspectives. Eur J Pharmacol. 2002;440(2-3):269-279.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
68. Verdich C, Flint A, Gutzwiller JP; et al. A meta-analysis of the effect of glucagon-like-peptide 1 (7-36) amide on ad libitum energy fat intake in humans. J Clin Endocrinol Metab. 2001;86(9):4382-4389.
FREE FULL TEXT
69. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000;404(6778):661-671.
PUBMED
70. Pardini AW, Nguyen HT, Figlewicz DP; et al. Distribution of insulin receptor substrate-2 in brain areas involved in energy homeostasis. Brain Res. 2006;1112(1):169-178.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
71. Posey KA, Clegg DJ, Printz RL; et al. Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet. Am J Physiol Endocrinol Metab. 2009;296(5):E1003-E1012.
FREE FULL TEXT
72. Wisse BE, Kim F, Schwartz MW. Physiology: an integrative view of obesity. Science. 2007;318(5852):928-929.
FREE FULL TEXT
73. Schwartz TW. Pancreatic polypeptide: a hormone under vagal control. Gastroenterology. 1983;85(6):1411-1425.
WEB OF SCIENCE
| PUBMED
74. Batterham RL, Le Roux CW, Cohen MA; et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab. 2003;88(8):3989-3992.
ABSTRACT
75. Hazelwood RL. The pancreatic polypeptide (PP-fold) family: gastrointestinal, vascular, and feeding behavioural implications. Proc Soc Exp Biol Med. 1993;202(1):44-63.
FREE FULL TEXT
76. Edelman S, Maier H, Wilhelm K. Pramlintide in the treatment of diabetes mellitus. BioDrugs. 2008;22(6):375-386.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
77. Reinehr T, Stoffel-Wagner B, Roth CL, Andler W. High-sensitive C-reactive protein, tumor necrosis factor alpha, and cardiovascular risk factors before and after weight loss in obese children. Metabolism. 2005;54(9):1155-1161.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
78. Visser M. Higher levels of inflammation in obese children. Nutrition. 2001;17(6):480-481.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
79. Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D. Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab. 2007;92(5):1971-1974.
FREE FULL TEXT
80. Maffeis C, Silvagni D, Bonadonna R, Grezzani A, Banzato C, Tato L. Fat cell size, insulin sensitivity, and inflammation in obese children. J Pediatr. 2007;151(6):647-652.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
81. Kowalska I, Straczkowski M, Nikolajuk A; et al. Insulin resistance, serum adiponectin, and proinflammatory markers in young subjects with the metabolic syndrome. Metabolism. 2008;57(11):1539-1544.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
82. Weyer C, Funahashi T, Tanaka S; et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86(5):1930-1935.
FREE FULL TEXT
83. Rosenbaum M, Murphy EM, Heymsfield SB, Matthews DE, Leibel RL. Low dose leptin administration reverses effects of sustained weight reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab. 2002;87(5):2391-2394.
FREE FULL TEXT
84. Farooqi IS, Jebb SA, Langmack G; et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341(12):879-884.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
85. Qi Y, Takahashi N, Hileman SM; et al. Adiponectin acts in the brain to decrease body weight. Nat Med. 2004;10(5):524-529.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
86. Kos K, Harte AL, da Silva NF; et al. Adiponectin and resistin in human cerebrospinal fluid and expression of adiponectin receptors in the human hypothalamus. J Clin Endocrinol Metab. 2007;92(3):1129-1136.
FREE FULL TEXT
87. Steppan CM, Bailey ST, Bhat S; et al. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307-312.
FULL TEXT
| PUBMED
88. Liu F, Fan HQ, Qiu J; et al. A paradox: insulin inhibits expression and secretion of resistin which induces insulin resistance. World J Gastroenterol. 2008;14(1):95-100.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
89. Azuma K, Katsukawa F, Oguchi S; et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res. 2003;11(8):997-1001.
WEB OF SCIENCE
| PUBMED
90. Valsamakis G, McTernan PG, Chetty R; et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism. 2004;53(4):430-434.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
91. Lee JH, Chan JL, Yiannakouris N; et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab. 2003;88(10):4848-4856.
FREE FULL TEXT
92. Monzillo LU, Hamdy O, Horton ES; et al. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res. 2003;11(9):1048-1054.
WEB OF SCIENCE
| PUBMED
93. Vendrell J, Broch M, Vilarrasa N; et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res. 2004;12(6):962-971.
WEB OF SCIENCE
| PUBMED
94. Reinehr T, Roth CL, Menke T, Andler W. Resistin concentrations before and after weight loss in obese children. Int J Obes (Lond). 2006;30(2):297-301.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
95. Yang Q, Graham TE, Mody N; et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436(7049):356-362.
FULL TEXT
| PUBMED
96. Graham TE, Yang Q, Bluher M; et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006;354(24):2552-2563.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
97. Cho YM, Youn BS, Lee H; et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care. 2006;29(11):2457-2461.
FREE FULL TEXT
98. Lee DC, Lee JW, Im JA. Association of serum retinol binding protein 4 and insulin resistance in apparently healthy adolescents. Metabolism. 2007;56(3):327-331.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
99. Reinehr T, Stoffel-Wagner B, Roth CL. Retinol-binding protein 4 and its relation to insulin resistance in obese children before and after weight loss. J Clin Endocrinol Metab. 2008;93(6):2287-2293.
FREE FULL TEXT
100. Araki S, Dobashi K, Kubo K; et al. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity (Silver Spring). 2008;16(2):384-388.
FULL TEXT
| PUBMED
101. Revollo JR, Körner A, Mills KF; et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007;6(5):363-375.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
102. Rongvaux A, Shea RJ, Mulks MH; et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol. 2002;32(11):3225-3234.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
103. Chen MP, Chung FM, Chang DM; et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006;91(1):295-299.
FREE FULL TEXT
104. Dogru T, Sonmez A, Tasci I; et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract. 2007;76(1):24-29.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
105. López-Bermejo A, Chico-Julia B, Fernandez-Balsells M; et al. Serum visfatin increases with progressive β-cell deterioration. Diabetes. 2006;55(10):2871-2875.
FREE FULL TEXT
106. Davutoglu M, Ozkaya M, Guler E; et al. Plasma visfatin concentrations in childhood obesity: relationships with insulin resistance and anthropometric indices. Swiss Med Wkly. 2009;139(1-2):22-27.
PUBMED
107. Haider DG, Holzer G, Schaller G; et al. The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr. 2006;43(4):548-549.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
108. Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab. 2007;92(12):4783-4791.
FREE FULL TEXT
109. Körner A, Böttcher Y, Enigk B, Kiess W, Stumvoll M, Kovacs P. Effects of genetic variation in the visfatin gene (PBEF1) on obesity, glucose metabolism, and blood pressure in children. Metabolism. 2007;56(6):772-777.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
110. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type-2 diabetes. Diabetes Care. 2005;28(5):1092-1100.
FREE FULL TEXT
111. Dakin CL, Small CJ, Batterham RL; et al. Peripheral oxyntomodulin reduces food intake ad body weight gain in rats. Endocrinology. 2004;145(6):2687-2695.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
112. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology. 2004;127(2):546-558.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
113. Wynne K, Park AJ, Small CJ; et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond). 2006;30(12):1729-1736.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
114. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf. 2007;30(12):1127-1142.
WEB OF SCIENCE
| PUBMED
115. Field BC, Wren AM, Cooke D, Bloom SR. Gut hormones as potential new targets for appetite regulation and the treatment of obesity. Drugs. 2008;68(2):147-163.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
116. Roth JD, Roland BL, Cole RL; et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A. 2008;105(20):7257-7262.
FREE FULL TEXT
117. Batterham RL, Cohen MA, Ellis SM; et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003;349(10):941-948.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
118. Bailey CJ. Drugs on the horizon for diabesity. Curr Diab Rep. 2005;5(5):353-359.
FULL TEXT
| PUBMED
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
|
